Koroku, Miki & Omori, Teppei & Kambayashi, Harutaka & Murasugi, Shun & Kuriyama, Tomoko & Ikarashi, Yuichi & Yonezawa, Maria & Arimura, Ken & Karasawa, Kazunori & Hanafusa, Norio & Kawana, Masatoshi & Tokushige, Katsutoshi.
Scientific corner
Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19
Intestinal Research. 2021 DOI:10.5217/ir.2020.00148.
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
Contact UsFor more information
Contact Us